Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.

Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A, Cross W, Dearnaley DP, Douis H, Gilbert D, Gillessen S, Jones RJ, Langley RE, MacNair A, Malik Z, Mason MD, Matheson D, Millman R, Parker CC, Ritchie AWS, Rush H, Russell JM, Brown J, Beesley S, Birtle A, Capaldi L, Gale J, Gibbs S, Lydon A, Nikapota A, Omlin A, O'Sullivan JM, Parikh O, Protheroe A, Rudman S, Srihari NN, Simms M, Tanguay JS, Tolan S, Wagstaff J, Wallace J, Wylie J, Zarkar A, Sydes MR, Parmar MKB, James ND.

Ann Oncol. 2019 Sep 27. pii: mdz396. doi: 10.1093/annonc/mdz396. [Epub ahead of print]

PMID:
31560068
2.

Radiotherapy for metastatic prostate cancer-Authors' reply.

Parker CC, James ND, Brawley CD, Clarke NW, Parmar MKB.

Lancet. 2019 Sep 7;394(10201):830. doi: 10.1016/S0140-6736(19)31829-X. No abstract available.

PMID:
31498099
3.

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.

Hoyle AP, Ali A, James ND, Cook A, Parker CC, de Bono JS, Attard G, Chowdhury S, Cross WR, Dearnaley DP, Brawley CD, Gilson C, Ingleby F, Gillessen S, Aebersold DM, Jones RJ, Matheson D, Millman R, Mason MD, Ritchie AWS, Russell M, Douis H, Parmar MKB, Sydes MR, Clarke NW; STAMPEDE Investigators.

Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30620-7. doi: 10.1016/j.eururo.2019.08.006. [Epub ahead of print]

PMID:
31447077
4.

Impact of montelukast and fluticasone on quality of life in mild pediatric sleep apnea.

Bluher AE, Brawley CC, Cunningham TD, Baldassari CM.

Int J Pediatr Otorhinolaryngol. 2019 Oct;125:66-70. doi: 10.1016/j.ijporl.2019.06.027. Epub 2019 Jun 26.

PMID:
31260810
5.

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.

Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O'Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR; Systemic Therapy for Advanced or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.

Lancet. 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3. Epub 2018 Oct 21.

6.

The Impact of Disruption of the Care Delivery System by Commercial Laboratory Testing in a Children's Health Care System.

Rogers BB, Adams JL, Carter AB, Uwindatwa F, Brawley CB, Cochran CG, Bryan LN, Weinzierl EP, Prahalad S.

Arch Pathol Lab Med. 2019 Jan;143(1):115-121. doi: 10.5858/arpa.2017-0529-OA. Epub 2018 May 23.

PMID:
29790786
7.

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators.

N Engl J Med. 2017 Jul 27;377(4):338-351. doi: 10.1056/NEJMoa1702900. Epub 2017 Jun 3.

8.

Risk factors for quantity not sufficient sweat collection in infants 3 months or younger.

Collins MN, Brawley CB, McCracken CE, Shankar PR, Schechter MS, Rogers BB.

Am J Clin Pathol. 2014 Jul;142(1):72-5. doi: 10.1309/AJCPLHG2BUVBT5LY.

PMID:
24926088
9.

Characterization of engineered actin binding proteins that control filament assembly and structure.

Brawley CM, Uysal S, Kossiakoff AA, Rock RS.

PLoS One. 2010 Nov 12;5(11):e13960. doi: 10.1371/journal.pone.0013960.

10.

JAK-STAT signal inhibition regulates competition in the Drosophila testis stem cell niche.

Issigonis M, Tulina N, de Cuevas M, Brawley C, Sandler L, Matunis E.

Science. 2009 Oct 2;326(5949):153-6. doi: 10.1126/science.1176817.

11.

Dedifferentiating spermatogonia outcompete somatic stem cells for niche occupancy in the Drosophila testis.

Sheng XR, Brawley CM, Matunis EL.

Cell Stem Cell. 2009 Aug 7;5(2):191-203. doi: 10.1016/j.stem.2009.05.024.

12.

An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.

Rizk SS, Luchniak A, Uysal S, Brawley CM, Rock RS, Kossiakoff AA.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11011-5. doi: 10.1073/pnas.0904907106. Epub 2009 Jun 22.

13.

Unconventional myosin traffic in cells reveals a selective actin cytoskeleton.

Brawley CM, Rock RS.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9685-90. doi: 10.1073/pnas.0810451106. Epub 2009 May 28.

14.

A myosin motor that selects bundled actin for motility.

Nagy S, Ricca BL, Norstrom MF, Courson DS, Brawley CM, Smithback PA, Rock RS.

Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9616-20. doi: 10.1073/pnas.0802592105. Epub 2008 Jul 3.

15.

Regeneration of male germline stem cells by spermatogonial dedifferentiation in vivo.

Brawley C, Matunis E.

Science. 2004 May 28;304(5675):1331-4. Epub 2004 May 13.

Supplemental Content

Loading ...
Support Center